Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Study at a glance

From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

ClinicalTrials.gov ID

NCT04379050

Acronym / sponsor ID

M15-737

Conditions

Parkinson's Disease (PD)

Keywords

Parkinson's Disease (PD), ABBV-951, Levodopa/Carbidopa (LD/CD), Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP)

Phase

Phase 3

Study type

Interventional

Recruitment status

Completed

Enrolment

130 participants (actual)

Lead sponsor

AbbVieIndustry (pharma, biotech, devices)

Study start

8 Jun 2020 (actual)

Primary completion

17 Apr 2026 (actual)

Study completion

17 Apr 2026 (actual)

First posted

7 May 2020 (actual)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose

Treatment

Allocation

Not applicable

Intervention model

Single group

Masking

None (open label)

Number of arms

1

Who may qualify

Ages

30 years and older

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Primary outcome

1. Percentage of Participants With Adverse Events (AE)

   Time frame: Up To Week 96

   An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of the study drug or device as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Adverse Events of Special Interest (AESI) - polyneuropathy, weight loss, hallucinations/psychosis, and somnolence will be monitored throughout the study.

2. Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation Scale

   Time frame: Up To Week 96

   The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an eight-point numeric scale used to assess irritation at the infusion site area (0 being "no evidence of irritation" and 7 being "strong reaction spreading beyond the test site").

3. Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation Scale

   Time frame: Up To Week 96

   The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an A to G letter grade scale, used to assess irritation at the infusion site area (A being "no finding" to G being "Small petechial erosions and/or scabs").

4. Change in Clinical Laboratory Test Data

   Time frame: Up To Week 96

   Number of participants with clinically significant change from baseline in laboratory parameters (hematology, biochemistry, coagulation, and urinalysis) will be reported throughout the study.

5. Change in Vital Signs Measurements

   Time frame: Up To Week 96

   Number of participants with clinically significant change from baseline in vital signs will be reported throughout the study.

6. Change From Baseline in Electrocardiograms (ECGs)

   Time frame: Up To Week 96

   Change from baseline in 12-lead ECGs on heart rate, RR interval, PR interval, QRS duration, and QT interval will be monitored throughout the study.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
• Individual participant dataSharing planned: Yes. AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Related trials for Parkinson's Disease (PD)

• Not yet recruiting

  Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.

  Stroke, Parkinson's Disease (PD)

• Active, not recruitingPhase 1/2

  Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease

  Parkinson Disease (PD)

• RecruitingObservational study

  Parkinson's Disease in Type 1 Gaucher Disease

  Parkinson Disease (PD), Type 1 Gaucher Disease

• Not yet recruitingPhase 1

  AAV2-hAADC for Parkinson's Disease (PDCS-01)

  Parkinson's Disease (PD), Early Onset Parkinson Disease

• Recruiting

  Effects of Microelectrode-based Brain Stimulation in Humans

  Essential Tremor, Parkinsons Disease (PD)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

51 sites in 13 countries: see every site and its status.